ArticleFrontiers in oncology2026
Quantitative phosphoproteomic profiling of CCL5/CCR5 signaling cascade in melanoma cells.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The CCL5/CCR5 axis plays a pivotal role in tumor progression and metastasis. We previously reported CCR5 promoted melanoma EMT and metastasis by upregulating TGFβ1 expression via the PI3K/AKT/GSK3β pathway. However, the full spectrum of downstream events triggered by CCR5 activation remains poorly understood. Methods: Here we employed quantitative phosphoproteomics to profile dynamic phosphorylation events in B16/F10 cells following CCL5 stimulation at three time points (5, 10 and 30 min). Moreover, to specifically dissect CCR5-mediated phosphorylation events distinct from other CCL5 receptors, we performed comparative phosphoproteomics between CCR5 knockout and wild type cells at the 5-min stimulation timepoint. Results: Temporal analysis revealed that CCL5 treatment modulated 256, 134, and 83 phosphosites at these respective time points. In total, 393 phosphosites across 315 phosphoproteins exhibited significant regulation. The comparative phosphoproteomics between CCR5 knockout and wild type cells identified 52 phosphoproteins and their temporal dynamics were illustrated. Gene Ontology enrichment analysis revealed that CCL5/CCR5 axis participated in various biological processes, particularly cell cycle regulation. Notably, upon CCL5 stimulation, three cell cycle-associated proteins-CEP131, KHDRBS1, and MAPK6-underwent phosphorylation activation, but this activation was remarkably prevented by CCR5 knockout. Overall. these findings provide a comprehensive phosphorylation resource for dissecting the molecular mechanisms underlying CCL5/CCR5-facilitated tumor progression and identifying potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.